|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hepatitis B surface antigen (HBsAg) decline was significantly associated with elevated CD86<sup>+</sup> pDC% (r = 0.348, P = 0.015) during PEG-IFN-α-2a treatment.
|
29791282 |
2018 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
IFN-α-mediated Base Excision Repair Pathway Correlates with Antiviral Response Against Hepatitis B Virus Infection.
|
28983111 |
2017 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
A one-year course of Peg-IFN has the advantage of providing immune-mediated control of the hepatitis B virus (HBV) infection, the possibility of achieving a sustained off-treatment response in nearly 30% of the patients and ultimately, HBsAg loss in approximately 30%-50% of the latter patients during long-term off treatment follow-up.
|
29427498 |
2018 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
A total of 210 patients with chronic hepatitis C genotype 1 of high viral load (baseline serum hepatitis C virus RNA > 5.0 log10 IU/mL) were divided into two groups by type of treatment: triple therapy with telaprevir, pegylated-interferon-α (PEG-IFNα), and ribavirin (RBV) for 24 wk (n = 88), or dual therapy with PEG-IFNα and RBV for 48 wk (n = 122).
|
25914481 |
2015 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
A total of 212 hepatitis B e antigen (HBeAg)-positive patients treated with PEG-IFN monotherapy were enrolled in this study.
|
24517415 |
2015 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
A total of 257 patients with chronic HBV, treated with PEG-IFN for 48 weeks, were identified from 13 tertiary hospitals included in the hepatitis B database of the Thai Association for the Study of the Liver (THASL).
|
28635613 |
2018 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
A total of 30 patients with CHB who achieved HBsAg seroclearance following peg-IFN-α therapy and an additional 30 age-, gender-, hepatitis B e antigen (HBeAg) status- and hepatitis B virus genotype-matched patients with CHB without HBsAg seroclearance following peg-IFN-α therapy, were enrolled as a discovery cohort.
|
25324041 |
2015 |
|
Hepatitis B
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A total of 39 single nucleotide polymorphism loci in 23 genes of the TLR-IFN pathway and four HLA polymorphism loci associated with chronic HBV infection identified by GWAS were selected for genotyping.
|
25469587 |
2015 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although IFN has been used in the treatment of viral hepatitis for more than a decade, the role of IFN-alpha-receptor in HBV infection has not been intensively studied.
|
19103527 |
2008 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Among children with hepatitis B envelope antigen-positive genotype C chronic HBV infection, we compared the efficacy of combination therapy with nucleotide analogues and IFN-α in 11 children with 12 historical cases treated with IFN monotherapy.
|
29981262 |
2018 |
|
Hepatitis B
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Based on these results, precore mutants do respond to IFN, and therefore, IFN is indicated in patients with HBeAb, especially those with low serum HBV DNA levels.
|
8745316 |
1995 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Chronic HCV and HBV infection and IFN-based HCV therapy were not associated with DM.
|
29901821 |
2018 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Clearance of Hepatitis B e antigen (HBeAg) was also more frequent in NASVAC group compared to Peg-IFN recipients.
|
30133478 |
2018 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Compared with lower doses and shorter durations, the licensed PEG-IFNα-2a treatment regimen (180 μg/48 weeks) was the most efficacious and beneficial for HBeAg-positive patients predominantly infected with hepatitis B virus genotypes B or C.
|
22045673 |
2011 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Conclusion: These findings highlight a host gene, UBE2L3, contributing to the susceptibility to persistent HBV infection; UBE2L3 may be involved in IFN-mediated viral suppression and serve as a potential target in the prevention and treatment of HBV infection.
|
30614547 |
2019 |
|
Hepatitis B
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Defining an "immediate virological response (IVR)" as the loss of serum hepatitis C virus (HCV) RNA 7 d after the first administration of PEG-IFN alpha, we conducted a 12-wk course of PEG-IFN alpha2a monotherapy without the addition of ribavirin for 38 patients who had low pretreatment HCV RNA load and exhibited IVR.
|
20333792 |
2010 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Endogenous HBV-CpG ODNs from the HBV genome induce IFN-α production so that nanoparticle-encapsulated HBV-CpG may act as an HBsAg vaccine adjuvant and may also represent a potent therapeutic agent for the treatment of chronic HBV infection.
|
23907803 |
2014 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Extended treatment with PEG IFNα-2a with lamivudine or adefovir for 96 weeks is a promising strategy to achieve high rates of sustainable HBeAg and HBsAg seroconversion and HBV DNA suppression in patients with HBeAg-positive CHB.
|
23615131 |
2013 |
|
Hepatitis B
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
For HBeAg-positive patients and HBeAg-negative patients with genotype D infection, PEG-IFN therapy could be terminated early at week 12 or 24 in primary non-responders defined by the Hepatitis B surface antigen stopping rules.
|
24738850 |
2014 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Higher IFN-<i>λ</i>3 concentrations are associated with response to HBV vaccination, self-limited HBV infection, and HCV resolution.
|
29226133 |
2017 |
|
Hepatitis B
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
His serum hepatitis C virus (HCV) RNA level became undetectable 1 week after the initiation of peg-IFN-alpha2b plus ribavirin treatment.
|
17287904 |
2006 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, these sustained response rates can be significantly increased by carefully selecting candidates for PEG-IFN therapy based upon baseline ALT and HBV DNA levels, viral genotype and IL28B polymorphisms, by extending PEG-IFN therapy beyond 48 weeks and, most importantly, by applying early on-treatment stopping rules based upon HBsAg kinetics.
|
23286860 |
2013 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Identifying the key negative factors and elucidating the regulating mechanism are essential for improving anti-HBV (hepatitis B virus) efficacy of IFNα.
|
30723923 |
2019 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Impaired expression and function of TLR8 in chronic HBV infection and its association with treatment responses during peg-IFN-α-2a antiviral therapy.
|
28236535 |
2017 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, a 24-month course of treatment with 6 MU IFN-alpha2b was well tolerated by most patients, led to sustained suppression of HBV in one third, and attenuated hepatitis in 81% of patients.
|
9398007 |
1997 |